ABOS Earnings & Financial Statements
Acumen Pharmaceuticals, Inc.
$1.75
-$0.07(-3.86%)
31
Overall
60
Value
18
Tech
15
Quality
Market Cap
$126.19M
Volume
619.66K
52W Range
$1.50 - $3.60
Target Price
$7.75
ABOS earnings and financial statements: Acumen Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ABOS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | $5.0K | $43.0K | $66.0K |
| Operating income | -$123.83M | -$114.02M | -$61.14M | -$45.24M | -$19.58M |
| EBITDA | -$116.93M | -$98.08M | -$52.19M | -$42.69M | -$100.45M |
| Net income | -$121.33M | -$102.33M | -$52.37M | -$42.86M | -$100.61M |
| EPS (diluted) | $-2.00 | $-1.71 | $-1.08 | $-1.06 | $-5.02 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $122.83M | $238.99M | $310.13M | $196.59M | $230.33M |
| Total liabilities | $52.40M | $57.18M | $43.15M | $7.81M | $5.15M |
| Shareholders’ equity | $70.43M | $181.82M | $266.97M | $188.78M | $225.18M |
| Cash and equivalents | $53.99M | $35.63M | $66.89M | $130.10M | $122.16M |
| Long-term debt | $22.40M | $29.42M | $29.90M | - | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$115.54M | -$86.22M | -$43.06M | -$35.15M | -$17.96M |
| Capital expenditure | -$88.0K | -$16.0K | -$21.0K | -$161.0K | -$40.0K |
| Free cash flow | -$115.63M | -$86.23M | -$43.09M | -$35.31M | -$18.00M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABOS | $1.75 | -3.9% | 619.66K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Acumen Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW